| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
|
| [2] |
Wu YL, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase Ⅲ clinical trial[J]. J Thorac Oncol, 2019, 14(5): 867-875. DOI: 10.1016/j.jtho.2019.01.006.
|
| [3] |
Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC[J]. N Engl J Med, 2020, 383(14): 1328-1339. DOI: 10.1056/NEJMoa1917346.
|
| [4] |
Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies[J]. Nat Rev Drug Discov, 2022, 21(7): 495-508. DOI: 10.1038/s41573-021-00259-5.
|
| [5] |
邓隽军, 赵大勇, 李淼. 免疫检查点抑制剂在非小细胞肺癌治疗中的不良反应及危险因素[J]. 国际肿瘤学杂志, 2023, 50(9): 564-568. DOI: 10.3760/cma.j.cn371439-20230404-00108.
|
| [6] |
Suijkerbuijk KPM, van Eijs MJM, van Wijk F, et al. Clinical and translational attributes of immune-related adverse events[J]. Nat Cancer, 2024, 5(4): 557-571. DOI: 10.1038/s43018-024-00730-3.
|
| [7] |
Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018, 19(10): 1338-1350. DOI: 10.1016/S1470-2045(18)30495-9.
pmid: 30213452
|
| [8] |
Tan S, Day D, Nicholls SJ, et al. Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: CardioOncology state-of-the-art review[J]. JACC CardioOncol, 2022, 4(5): 579-597. DOI: 10.1016/j.jaccao.2022.09.004.
|
| [9] |
Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combi-nations, and clinical outcome[J]. Front Pharmacol, 2017, 8: 561. DOI: 10.3389/fphar.2017.00561.
|
| [10] |
Moulinet T, Moussu A, Pierson L, et al. The many facets of immune-mediated thrombocytopenia: principles of immunobiology and immunotherapy[J]. Blood Rev, 2024, 63: 101141. DOI: 10.1016/j.blre.2023.101141.
|
| [11] |
Zhou C, Wang Z, Sun Y, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial[J]. Lancet Oncol, 2022, 23(2): 220-233. DOI: 10.1016/S1470-2045(21)00650-1.
pmid: 35038432
|
| [12] |
Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728. DOI: 10.1001/jamaoncol.2018.3923
pmid: 30242316
|
| [13] |
Mititelu A, Onisâi MC, Rosca A, et al. Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options[J]. Int J Mol Sci, 2024, 25(4): 2163. DOI: 10.3390/ijms25042163.
|
| [14] |
Wu D, Liu Y, Pang N, et al. PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and Treg/Th17 cells subtypes in immune thrombocytopenic purpura patients[J]. Medicine (Baltimore), 2019, 98(43): e17608. DOI: 10.1097/MD.0000000000017608.
|
| [15] |
Assi HA, Asch AS, Machiorlatti M, et al. Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy[J]. Future Sci OA, 2020, 6(7): FSO581. DOI: 10.2144/fsoa-2020-0021.
|
| [16] |
Li S, Lu Z, Wu S, et al. The dynamic role of platelets in cancer progression and their therapeutic implications[J]. Nat Rev Cancer, 2024, 24(1): 72-87. DOI: 10.1038/s41568-023-00639-6.
pmid: 38040850
|
| [17] |
中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会. 中国肿瘤药物相关血小板减少诊疗专家共识(2023版)[J]. 中华医学杂志, 2023, 103(33): 2579-2590. DOI: 10.3760/cma.j.cn112137-20230409-00575.
|
| [18] |
Chen Y, Xu Y, Li H, et al. A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia[J]. N Engl J Med, 2024, 390(23): 2178-2190. DOI: 10.1056/NEJMoa2400409.
|
